Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients

• Status: Completed
• Trial end date: 2017-01-23
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the pharmacokinetic and safety for the esomeprazole use for schizophrenia

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: National Taiwan University
• Treatments: Esomeprazole

Criteria

Inclusion criteria

1. 20-65 years old

2. Diagnosed as DSM-IV schizophrenia

3. No adjustment of dose of major antipsychotics for at least 4 weeks

4. Competence for inform consent

Exclusion criteria

1. Diagnosed with schizoaffective disorder or bipolar affective disorder or organic psychotic disorder

2. Meet the diagnostic criteria of any substance abuse or dependence in the past 6 months

3. History or evidence of any clinically significant medical or neurological disease, such as autoimmune disease, cancer, epilepsy, etc.

4. Mental retardation or pervasive developmental disorders

5. Past history of allergy to Esomeprazole

6. patient who is taking clozapine、 Depakin or Diazepam

7. Pregnant

8. The patient is under the order of involuntary admission